BACKGROUND: Autologous bone grafting is currently considered as the gold standard to restore bone defects. However, clinical benefit is not guaranteed and there is an associated 8-39% complication rate. This resulted in the development of alternative (synthetic) CONCLUSION: The requirements of an optimal bone substitute are related to size and location of the defect. Calcium phosphate grafts have been used for most trauma and orthopaedic surgery procedures. Calcium sulphates were mainly used to restore bone defects after tumour resection surgery and offer minimal structural support. Bioactive glass remains a potential alternative; however its use has only been studied to a limited extent.
Introduction
The treatment of fractures remains a continuous challenge for trauma and orthopaedic surgeons. Although most fractures heal uncomplicated, 5-10% of patients encounter problems due to bone defects, impaired fracture healing, or a combination of both [1]. Significant bone defects or post-traumatic complications such as delayed union, non-union or malunion may require bone-grafting in order to fill the defect. Bone grafts fill voids, provide support, and therefore may enhance the biological repair of the defect. Bone grafting is a common surgical procedure, carried out in approximately 10% of all skeletal reconstructive surgery cases [2] .
Worldwide, an estimated 2.2 million grafting procedures are performed each year [3, 4] .
Bone healing differs from any other soft tissue since it heals through the generation of new bone rather than by forming fibrotic tissue. Bone repair requires four critical elements:
(1) osteogenic cells (e.g., osteoblasts or progenitor cells); (2) osteoinductive signals provided by growth factors; (3) an osteoconductive matrix; and (4) adequate blood and nutrient supply [5] . Therefore, bone grafts are often described by the terms osteogenicity, osteoinductivity and osteoconductivity. Osteogenicity is the presence of bone forming cells within the bone graft [6, 7] . Osteoinductivity is the ability of a graft to stimulate or promote bone formation [8] .
Osteoconductivity is the ability of the graft to function as a scaffold for ingrowth of new bone and sprouting capillaries [9] .
Autologous bone, mostly harvested from the iliac crest, is considered the gold standard since it provides a scaffold for bone ingrowth, contains living bone cells that offer osteogenesis, and contains growth factors that stimulate osteoinduction [6] . However, as the cellular elements do not necessarily survive transplantation, the clinical benefit is not guaranteed [10] . In addition, the harvesting of autologous bone lengthens the surgical procedure, and the graft amount may be insufficient, or the form inappropriate. Moreover, autograft harvesting is associated with an 8-39% risk of complications, e.g., infection, hematoma, nerve and urethral injury, pelvic instability, cosmetic disadvantages, postoperative pain and chronic pain at the donor site [11] [12] [13] [14] . Furthermore, autografting is normally not recommended for elderly or paediatric patients or for patients with malignant or infectious disease. Alternative strategies like allo-, and xenotransplantation have major biocompatibility disadvantages compared with autografting [15, 16] , and as such their use is suboptimal.
Due to complications and limitations associated as reported, alternative bone substitutes were needed. Based upon the above, the perfect bone substitute is osteoconductive, osteoinductive, biocompatible, and bioresorbable. Moreover, it should induce minimal or no fibrotic reaction, undergo remodelling and support new bone formation. From a mechanical point of view bone substitutes should have similar strengths to that of the bone being replaced. Finally, it should be cost-effective and ought to be available in the amount required.
Technological evolution and better understanding of bone-healing biology resulted in the development of numerous alternative bone substitutes. Multiple products, containing (combinations of) hydroxyapatite, tricalcium phosphate, dicalcium phosphate, calcium sulphate (plaster of Paris), or bioactive glass are currently available for use in trauma and orthopaedic surgery. However, an evidence-based guideline to assist surgeons in selecting the best product for specific clinical indications is not available yet. The aim of the current study was to provide a comprehensive overview of literature data of bone substitutes registered in the Netherlands for use in trauma and orthopaedic surgery. An overview of products, their composition, their biological and biomechanical characteristics as well as their clinical indications in trauma and orthopaedic surgery is provided.
Methods

Product selection
Products were selected based upon the following criteria: (1) products composed of (combinations of) calcium phosphate, calcium sulphate or bioactive glass; (2) indicated for use in trauma and orthopaedic surgery; and (3) available in the Netherlands on October 12, 2009. Products were excluded if they could only be used in combination with adjunctive (e.g., bone marrow aspirate, growth factors, or antibiotics) or if they were only indicated for use in craniomaxillofacial surgery.
Literature search
Brand names of all products (see Table 1 ) were used as search terms in three available online databases: Embase, PubMed, and Cochrane. Databases were searched from the earliest date available until July 1, 2010. Titles and abstracts were screened by two researchers (JVDS and YEM). Only papers that reported on structural, biological or biomechanical properties, or on clinical indications in trauma and orthopaedic surgery, and were written in English, German, or Dutch were considered eligible. The full text of all eligible papers retrieved from PubMed and Cochrane were read by two researchers (JVDS and YEM), papers found in Embase were read by three researchers (JVDS, GHVK, and YEM). All references in the selected manuscripts were reviewed in order to ensure that no papers had been missed with the chosen search strategy. For final inclusion a manuscript had to report on structural, biological or biomechanical properties of the pure product or on their use in trauma and orthopaedic surgery. Data regarding study design, species, structural, biological, biomechanical, and clinical findings were collected in a database, and are summarized below. Manuscripts reporting on clinical indications of bone substitutes for trauma and orthopaedic surgery were given a level of evidence as described by Mahid et al [17] .
Results
Eighteen bone substitute products were selected. All products were commercially available at Table 2 .
Calcium phosphate
In the eighties, calcium phosphate salts such as tricalcium phosphate (TCP) and hydroxyapatite (HA) were introduced for clinical use [18] . Multiple calcium phosphate grafts are available with different application forms (eg., pastes, putties, solid matrices, granules).
Based upon their chemical composition, calcium phosphates can be separated into hydroxyapatite (HA), tricalcium phosphate (TCP) and composite grafts (Table 1) . The latter simply indicating a combination of two or more calcium phosphates.
Structural properties
Structural properties are related to production methods. 
Clinical indications
Each clinical indication requires specific structural, biological and biomechanical properties of graft material. An overview of clinical indications in trauma and orthopaedic surgery of each product is given in [88] . Besides, Pro
Osteon 500 ® was also used for distal radius fractures [89] .
Tricalcium phosphate grafts may be used in the upper and lower extremity. Vitoss ® is an option to treat fractures of the tibia or calcaneus, but was also used in the upper extremity, especially in the humerus [90] . ChronOS TM was used as bone graft in the posterior stabilization and interlaminar fusion of a vertebral fracture type Magerl B2.3 [88] .
Of the calcium phosphate cements, Norian SRS ® have been tested most extensively. In the upper extremity, union of fractures of the humerus [91] and distal radius [92] [93] [94] [95] [96] [97] [98] [99] [100] has been achieved. Norian SRS ® is effective in maintaining realignment of fracture parts after reduction of displaced or comminuted distal radius fractures. This technique resulted in accelerated rehabilitation, and better final outcomes after two years [93, 96, 97] . In the lower extremities, Norian SRS ® can be used to fill metaphyseal bone defects in tibia plateau fractures [101] [102] [103] [104] [105] [106] . Good to excellent results at one year after trauma was shown in 95% of cases [106] . Nonetheless, loss of reduction occurred in 8-20% of cases and long term results
showed a 20% post-traumatic osteoarthritis rate [105, 106] . Adding Norian SRS ® to sliding screw fixation for unstable trochanteric fractures resulted in modest improvement of fracture healing [107] . Average movement of sliding screw was significantly reduced by augmentation with Norian SRS ® after six weeks [108] . In calcaneal fractures this grafting material allows full weight bearing four weeks after surgery compared to eight weeks with autologous augmentation [109] . Another study shows postoperative full weight bearing as early as three weeks shows in standard open reduction with internal fixation in calcaneal fractures [60] .
BoneSource ® can be used safely when filling of traumatic bone voids is required.
Graft sites included the humerus (1), radius (3), femur (1), tibia (9), and calcaneus (7) and reduction was maintained in 83% [110] . However, BoneSource ® alone does not provide adequate fracture stability in distal radius fractures [111] . Calcibon ® is used for filling of metaphyseal cancellous bone defects and is was used to stabilize traumatic Magerl type A thoracolumbar fractures [112] . Calcibon ® augmentation in vertebral bodies improves pain and function en enables the treated vertebral body to regain height [113, 114] . 
Structural properties
No data on structural properties of calcium sulphate grafts has been found.
Biological properties
Calcium sulphates appear to function as a resorbable osteoconductive scaffold that provides the structural framework necessary for angiogenesis and osteogenesis while preventing soft tissue invasion by acting as a void filler; however, they lack not only osteogenic but also osteoinductive properties. Calcium sulphate is considered biocompatible, electing little or no macrophagic reaction, and is fully dissolved within 6-12 weeks [116] . MIIG ® X3 was found to be osteoconductive [117] [118] [119] . The use of OsteoSet ® resulted in a 8-35% new bone ingrowth in animal experiments [116, [120] [121] [122] [123] which was found to be equivalent to autogenous and allogenic bone grafts [116] . However, in two studies no osteoconductive potential of OsteoSet ® was noted [124, 125] . No data on osteoconductive properties of Bone Plast ® and Stimulan ® were found.
Biomechanical properties
Compression strength of OsteoSet ® and MIIG ® X3 were attained in similar experiments, using in vivo samples which were implanted in for 26 weeks in the humerus of dogs.
Compression strength of OsteoSet ® was 0.6-0.9MPa [121, 123] and of MIIG ® X3 0.6MPa [123] . Young's modulus of OsteoSet ® was 59MPa [121] . No data on biomechanical properties of Bone Plast ® and Stimulan ® was found.
Clinical indications
Calcium sulphate grafts are mainly used to fill bony voids resulting of tumour resection surgery. Kelly et al used MIIG ® X3 to graft bone defects of the distal tibia, patella, calcaneus, ileum, femur, and humerus [117] . But MIIG ® X3 may also be used to treat both proximal [118, 123] and distal tibia fractures [123] Twenty-one tibia plateau fractures were treated with MIIG ® X3 and internal fixation, resulting in complete fracture healing and graft resorption after 12 weeks [118] .
OsteoSet ® fills defects of the humerus, radius, ulna, femur, tibia, fibula and calcaneus [126] [127] [128] [129] [130] . However, OsteoSet ® may not provide sufficient biomechanical support as several stress fractures after grafting have been reported [129, 131] and a self-limiting local sterile inflammatory reaction occurred in 4 to 20% of graft sites [129, 132, 133] . In one case convulsions as complication with elevated calcium was reported after use of OsteoSet ® in a lumbar fracture [134] . Also Bone Plast ® may be indicated as it has been used in pelvic, humerus, calcaneus and femoral bone after aspiration of recurrent aneurysmal bone cysts [135] . No data on Stimulan ® was found.
Bioactive glass
Bioactive glasses are hard, solid (non-porous), materials consisting of four components:
sodium oxide, calcium oxide, silicon dioxide (silicate, the main component) and phosphorous [7] . By varying the proportions of sodium oxide, calcium oxide and silicon dioxide, soluble and non-resorbable grafts can be made [136] . Cortoss ® is the only bioactive glass that is available in the Netherlands..
Structural properties
Bioactive glasses can be manufactured into microspheres, fibers and porous implants.
Cortoss ® is available as a paste, but no data concerning other structural properties of Cortoss ® , such as porosity and pore size,was found.
Biological properties
Bone substitute materials within the group of bioactive glass display osteoinductive and osteoconductive properties [7] . They are bioactive, as they interacts with the body [137] .
Bioactivity depends upon the SiO 2 content; the bonding between bone and glass is best if the bioactive glass contains 45-52% SiO 2 [137] . The strong graft-bone bonding occurs as a result of the formation of a silicate rich layer after contact with body fluids. On top of this, a layer of hydroxyapatite will form, which directs new bone formation together with protein absorption.
The extracellular proteins attract macrophages, mesenchymal stem cells, and osteoprogenitor cells. Subsequently, the osteoprogenitor cells proliferate into matrix-producing osteoblasts [137, 138] . Cortoss ® has osteoconductive properties [139] , but is not resorbed [140] . It does not induce cytotoxicity [141] , and offers biocompatibility and reduced risk of thermal necrosis [142] .
Biomechanical properties
Bioactive glass posses superior mechanical strength compared with calcium phosphate products, as a result of a strong graft-bone bonding [7] . Cortoss ® has a compression strength of 91-179MPa with a shear strength of 8.4MPa, which is significantly higher than PMMA bone cements [143, 144] . Manufactures information also provides a Young's modulus of 6,400MPa and a tensile strength of 52MPa; however this was not confirmed in other studies.
Clinical indications
The first reports on clinical applications of bioactive glass emerge in the 1980s [145] . Since then, bioactive glass has been applied for craniofacial reconstructive surgery, dental surgery and trauma or orthopaedic surgery. [147, 148] . One case report was published in which successful treatment of an unstable distal radius fracture was described [140] .
Discussion
The repair of large bony defects resulting of trauma or disease remains a major problem in Overall, osteoconductive properties could be confirmed for almost all included calcium phosphates, calcium sulphates and for bioactive glass. Unfortunately, major differences in experimental design (e.g., animal model) and absence of a standardized scoring system to define quality and quantity of new bone formation troubles the direct comparison among included grafts.
In order to acquire osteoconductive properties, pore size and porosity, and the degradation potential of the bone substitute material are essential. A macroporous structure of pores ranging 150-500μm in size is considered optimal for ingrowth of new bone [149, 150] ..
In addition, interconnective pores increases new bone ingrowth [149, 151, 152] .
Microporosity (e.g., pores <5μm) is considered important for bioresorbable properties of the material [153] . Resorption rates differ substantially between the products, mainly due to their chemical composition. On average, sintered HA is rather inert, and hardly shows any resorption even after ten years. Tricalcium phosphate and calcium phosphate cement composites, on the other hand, are degraded within approximately two years as a result of osteoclastic activity [21] . Calcium sulphates are generally dissolved within 8-12 weeks [154] .
Resorption of bioactive glass is variable, and depends upon the relative amounts of sodium oxide, calcium oxide, silicon dioxide, and phosphorous present [7] .
Based upon their structure, hydroxyapatite and tricalcium phosphate ceramics have the advantage of offering a sufficient macroporous structure to facilitate new bone ingrowth.
Optimized pore size was confirmed for the products Endobon ® and ChronOS TM (Table 3) . On the other hand, rather quick resorption of calcium sulphate products provides space for new bone formation and prevents the early formation of fibrotic tissue; however, resorption may be completed before sufficient new bone formation. The same accounts for the biodegradable calcium phosphate cements, however their resorption time is slower compared with calcium sulphate products and depends mainly on chemical composition of the graft.
Besides optimal biological properties, bone substitutes should offer direct structural support to surrounding bone and soft tissues. The biomechanical strength is the resultant of a complex interplay between the bone and bone substitute material. In an ideal situation a bone void is grafted by a bone substitute material that offers biomechanical strength similar as the bone being replaced. However, the biomechanical behavior of implanted material may undergo changes as a resultant of in vivo interactions, e.g. osteointegration, bone incorporation, or bioresorption of the substitute material. The biomechanical properties of bone itself, on the other hand, differ according to their structure (cortical or cancellous) and function (weight-bearing or non weight-bearing). Grafting a defect with a bone substitute material that has a higher initial biomechanical strength than the surrounding bone may result in stress-shielding and subsequent bone resorption at the bone-implant interface, or may lead to delayed fractures along the bone-implant interface. Using a bone substitute material with a lower biomechanical strength than the surrounding bone may lead to delayed fractures due to the lack of biomechanical stability. As mentioned above, the different products have different resorption rates. Provided that the biodegradation process works as designed, each product may ultimately resorb and remodel back into normal bone. If that holds true, the long-term strength of the restored bone may be similar for different products.
Human cortical bone has a compression strength of 130-290MPa and a tensile strength of , whereas the compression strength of cancellous bone ranges between 2 and 38MPa [155] . Although not available for use in the Netherlands, and hence not included in this review, a properly designed RCT , and within the literature more well conducted RTCs has also been published on the use of α-BSM [156] . This shows that RCTs on efficacy of bone substitutes in trauma and orthopaedic surgery are feasible.
A potential weakness of this study could be the used search strategy which forms the basis of our conclusions. Included products were searched in multiple databases by using product name as search term. By this method we might have missed studies which did not specify the product being used. However, the aim of this systematic review was to provide an reviewed elsewhere [157, 158] .
Summary
The eighteen bone substitute materials available in The Netherlands represent a variety of forms, structure and chemical composition. Some of them have been investigated thoroughly, for other there is limited data available. Determining which material to use for different clinical indications is based on many factors including the size and location of the bone tissue defect as well as structural, biological and biomechanical properties of the graft itself.
Calcium phosphate grafts have been used for most trauma and orthopaedic surgery procedures when a grafting is necessary to restore bone defects. Calcium sulphates were mainly used to restore bone defects after tumour resection surgery and do not offer sufficient structural support to be used even in minimal weight baring bones. Bioactive glass remains an interesting alternative; however its use in trauma and orthopaedic surgery is only reported in a limited number of studies. To further improve decision making of bone substitute grafts to treat bony defects, more standardized research to explore the full potential of calcium phosphate, calcium sulphate and bioactive glass is recommended.
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